PrecisemAb Biotech has been honored by the Small and Medium Enterprise Administration, Ministry of Economic Affairs, as one of the “2025 Emerging High-Potential Startups.”
This recognition highlights our strong capabilities in innovative antibody drug development and our proprietary technology platforms.
We sincerely appreciate the nomination and support from the KMU Incubation Center, which enabled PrecisemAb to stand out among many outstanding teams, advance to the final round, and ultimately receive this honor.
This award not only affirms our R&D achievements and the dedication of our team, but also symbolizes PrecisemAb’s continuous progress in precision medicine and global collaboration. We will take this milestone as a driving force to accelerate the commercialization of our innovative technologies and work closely with our partners to reach new and impactful milestones.
